骨巨细胞瘤对狄诺沙单抗的组织病理学反应——附11例报告。

IF 1.4 4区 医学 Q4 ONCOLOGY
Rabish Kumar, Varuna Mallya, Shramana Mandal, Reena Tomar, Nita Khurana, Lalit Maini
{"title":"骨巨细胞瘤对狄诺沙单抗的组织病理学反应——附11例报告。","authors":"Rabish Kumar,&nbsp;Varuna Mallya,&nbsp;Shramana Mandal,&nbsp;Reena Tomar,&nbsp;Nita Khurana,&nbsp;Lalit Maini","doi":"10.4103/jcrt.jcrt_1777_21","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Giant cell tumor (GCT) of the bone is a locally aggressive primary bone tumor, that can rarely metastasize. Arising mostly in epiphysis of the long bones in young adults, the tumor is composed of mononuclear cells that are admixed with osteoclastic giant cells(OLGCs), which express RANK ligand and RANK respectively. Denosumab a monoclonal antibody against RANK ligand has been shown to reduce the tumor by causing bone lysis by inhibiting RANKL. Histological changes in 11 patients of GCT who were treated with denosumab are presented here.</p><p><strong>Materials and methods: </strong>Clinical records and slides of 11 patients of GCT who had been administered neoadjuvant denosumab were included in the study. Evaluation of pre and post therapy GCT specimens was performed by two pathologists (RK and VM). There were 4 males and 7 females. Their mean age was 30 years. All the patients received 120 mg denosumab subcutaneously every week with additional 120 mg on days 8 and 15 of therapy. The histological slides were reviewed and following points noted: 1) degree of ossification,2) fibrosis,3) loss of osteoclastic giant cells,4) proliferation of mononuclear cells,5) atypia,6) Permeation of osteoid by malignant cells.</p><p><strong>Results: </strong>Out of 11 cases, 2 cases did not show any significant histological improvement. 7 cases showed reduction in giant cells, increased fibrosis, enhanced mononuclear cell proliferation and ossification consistent with a pathological response. Atypia and osteoid permeation were noted in 2 cases which showed transformation to osteosarcoma.</p><p><strong>Conclusion: </strong>Denosumab treated giant cell tumor show dramatic histological changes. The post therapy lesions may bear no resemblance to pretherapy lesion. There may be complete resolution or may be confused with benign or malignant lesions Rarely they may show sarcomatous transformation. It is imperative that the pathologist is aware of these changes to prevent diagnostic pitfalls as it poses therapeutic and prognostic implications.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 3","pages":"768-772"},"PeriodicalIF":1.4000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Histopathological response to denosumab in giant cell tumours of bone - A review of 11 cases.\",\"authors\":\"Rabish Kumar,&nbsp;Varuna Mallya,&nbsp;Shramana Mandal,&nbsp;Reena Tomar,&nbsp;Nita Khurana,&nbsp;Lalit Maini\",\"doi\":\"10.4103/jcrt.jcrt_1777_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Giant cell tumor (GCT) of the bone is a locally aggressive primary bone tumor, that can rarely metastasize. Arising mostly in epiphysis of the long bones in young adults, the tumor is composed of mononuclear cells that are admixed with osteoclastic giant cells(OLGCs), which express RANK ligand and RANK respectively. Denosumab a monoclonal antibody against RANK ligand has been shown to reduce the tumor by causing bone lysis by inhibiting RANKL. Histological changes in 11 patients of GCT who were treated with denosumab are presented here.</p><p><strong>Materials and methods: </strong>Clinical records and slides of 11 patients of GCT who had been administered neoadjuvant denosumab were included in the study. Evaluation of pre and post therapy GCT specimens was performed by two pathologists (RK and VM). There were 4 males and 7 females. Their mean age was 30 years. All the patients received 120 mg denosumab subcutaneously every week with additional 120 mg on days 8 and 15 of therapy. The histological slides were reviewed and following points noted: 1) degree of ossification,2) fibrosis,3) loss of osteoclastic giant cells,4) proliferation of mononuclear cells,5) atypia,6) Permeation of osteoid by malignant cells.</p><p><strong>Results: </strong>Out of 11 cases, 2 cases did not show any significant histological improvement. 7 cases showed reduction in giant cells, increased fibrosis, enhanced mononuclear cell proliferation and ossification consistent with a pathological response. Atypia and osteoid permeation were noted in 2 cases which showed transformation to osteosarcoma.</p><p><strong>Conclusion: </strong>Denosumab treated giant cell tumor show dramatic histological changes. The post therapy lesions may bear no resemblance to pretherapy lesion. There may be complete resolution or may be confused with benign or malignant lesions Rarely they may show sarcomatous transformation. It is imperative that the pathologist is aware of these changes to prevent diagnostic pitfalls as it poses therapeutic and prognostic implications.</p>\",\"PeriodicalId\":15208,\"journal\":{\"name\":\"Journal of cancer research and therapeutics\",\"volume\":\"19 3\",\"pages\":\"768-772\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer research and therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/jcrt.jcrt_1777_21\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/jcrt.jcrt_1777_21","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

背景:骨巨细胞瘤(GCT)是一种局部侵袭性原发性骨肿瘤,很少发生转移。肿瘤主要发生在年轻人的长骨骨骺中,由单核细胞与破骨细胞巨细胞(OLGC)混合组成,这些细胞分别表达RANK配体和RANK。Denosumab是一种抗RANK配体的单克隆抗体,已被证明通过抑制RANKL引起骨溶解来减少肿瘤。本文介绍了11例接受狄诺沙单抗治疗的GCT患者的组织学变化。材料和方法:本研究纳入了11例接受新佐剂替诺沙单抗治疗的GCT患者的临床记录和幻灯片。由两名病理学家(RK和VM)对治疗前后的GCT标本进行评估。男4例,女7例。他们的平均年龄是30岁。所有患者每周皮下注射120 mg地诺沙单抗,并在治疗的第8天和第15天额外注射120 mg。回顾了组织学切片,并注意到以下几点:1)骨化程度,2)纤维化,3)破骨细胞巨细胞丢失,4)单核细胞增殖,5)异型性,6)恶性细胞渗透类骨。结果:11例中,2例组织学无明显改善。7例显示巨细胞减少、纤维化增加、单核细胞增殖增强和骨化与病理反应一致。2例表现为转化为骨肉瘤的患者出现非典型性和类骨渗透。结论:Denosumab治疗的巨细胞瘤表现出明显的组织学变化。治疗后的病变可能与治疗前的病变没有相似之处。可能完全消退,也可能与良性或恶性病变混淆。罕见的情况下,它们可能表现为肉瘤转化。病理学家必须意识到这些变化,以防止诊断失误,因为它会带来治疗和预后影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Histopathological response to denosumab in giant cell tumours of bone - A review of 11 cases.

Background: Giant cell tumor (GCT) of the bone is a locally aggressive primary bone tumor, that can rarely metastasize. Arising mostly in epiphysis of the long bones in young adults, the tumor is composed of mononuclear cells that are admixed with osteoclastic giant cells(OLGCs), which express RANK ligand and RANK respectively. Denosumab a monoclonal antibody against RANK ligand has been shown to reduce the tumor by causing bone lysis by inhibiting RANKL. Histological changes in 11 patients of GCT who were treated with denosumab are presented here.

Materials and methods: Clinical records and slides of 11 patients of GCT who had been administered neoadjuvant denosumab were included in the study. Evaluation of pre and post therapy GCT specimens was performed by two pathologists (RK and VM). There were 4 males and 7 females. Their mean age was 30 years. All the patients received 120 mg denosumab subcutaneously every week with additional 120 mg on days 8 and 15 of therapy. The histological slides were reviewed and following points noted: 1) degree of ossification,2) fibrosis,3) loss of osteoclastic giant cells,4) proliferation of mononuclear cells,5) atypia,6) Permeation of osteoid by malignant cells.

Results: Out of 11 cases, 2 cases did not show any significant histological improvement. 7 cases showed reduction in giant cells, increased fibrosis, enhanced mononuclear cell proliferation and ossification consistent with a pathological response. Atypia and osteoid permeation were noted in 2 cases which showed transformation to osteosarcoma.

Conclusion: Denosumab treated giant cell tumor show dramatic histological changes. The post therapy lesions may bear no resemblance to pretherapy lesion. There may be complete resolution or may be confused with benign or malignant lesions Rarely they may show sarcomatous transformation. It is imperative that the pathologist is aware of these changes to prevent diagnostic pitfalls as it poses therapeutic and prognostic implications.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.80
自引率
15.40%
发文量
299
审稿时长
6 months
期刊介绍: The journal will cover technical and clinical studies related to health, ethical and social issues in field of Medical oncology, radiation oncology, medical imaging, radiation protection, non-ionising radiation, radiobiology. Articles with clinical interest and implications will be given preference.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信